A Phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites

Journal of Pain and Symptom Management

Volumn 19, Issue 3, 2000, Pages 193-199

  Mackey, John R ^a   Wood, Lori ^b   Nabholtz, Jean Marc ^a   Jensen, John ^c   Venner, Peter ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Vancouver Island Cancer Centre   (Canada)

Author keywords

Malignant ascites; Paracentesis; Triamcinolone hexacetonide

Indexed keywords

TRIAMCINOLONE HEXACETONIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; APPENDIX TUMOR; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER; CARCINOMA; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DYSPNEA; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LIVER METASTASIS; MALE; MORTALITY; NAUSEA; OVARY CARCINOMA; PARACENTESIS; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT DISEASE; SURVIVAL TIME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ASCITES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PARACENTESIS; RECURRENCE; TRIAMCINOLONE ACETONIDE;

EID: 0034069424     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(00)00106-8     Document Type: Article

References (23)

1. Hird V., Thomas H., Stewart J.S.et al. Malignant ascites. review of the literature, and an update on monoclonal antibody-targeted therapy Eur J Obstet Gynecol Reprod Biol. 32:1989;37-45.
2. Ross G.J., Kessler H.B., Clair M.R.et al. Sonographically guided paracentesis for palliation of symptomatic malignant ascites. Am J Roentgenol. 153:1989;1309-1311.
3. Mackey J.R., Venner P.M. Malignant ascites. demographics, therapeutic efficacy and predictors of survival Ann Cancer Control Res. 6:1996;474-480.
4. Diaz-Buxo J.A., Chandler J.T., Farmer C.D.et al. Intraperitoneal infusion of non-absorbable steroids in the treatment of ascites and sterile peritonitis. J Dial. 4:1980;43-50.
5. Jones B.F., Trevillian P.R., Nandra R.S. Idiopathic ascites of haemodialysis. response to treatment Br Med J. 1:1976;877.
6. Bansal V.K., Popli S., Ing T.S.et al. Intraperitoneal infusion of a nonabsorbable steroid in hemodialysis-associated ascites. J Dial. 2:1978;379-385.
7. Pascual J.F., Melendez M.T., Rivera-Viera J.F. Local steroid therapy of refractory ascites associated with dialysis. J Pediatr. 94:1979;319-320.
8. Runyon B.A., Montano A.A., Akriviadis E.A.et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 117:1992;215-220.
9. Parsons S.L., Lang M.W., Steele R.J. Malignant ascites. a 2-year review from a teaching hospital Eur J Surg Oncol. 22:1996;237-239.
10. Belfort M.A., Stevens P.J., DeHaek K., Soeters R., Krige J.E. A new approach to the management of malignant ascites. a permanently implanted abdominal drain Eur J Surg Oncol. 16:1990;47-53.
11. Sabatelli F.W., Glassman M.L., Kerns S.R., Hawkins I.F. Jr. Permanent indwelling peritoneal access device for the management of malignant ascites. Cardiovasc Intervent Radiol. 17:1994;292-294.
12. Helzberg J., Greenberger N. Peritoneovenous shunts in malignant ascites. Dig Dis Sci. 30:1985;1104-1107.
13. Edney J., Hill A., Armstrong D. Peritoneovenous shunts palliate malignant ascites. Am J Surg. 158:1989;598-601.
14. Pockros P.J., Esrason K.T., Nguyen C.et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology. 103:1992;1302-1306.
15. Loggie B.W., Perini M., Fleming R.A.et al. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg. 63:1997;137-143.
16. Nagy J.A., Herzberg K.T., Dvorak J.M.et al. Pathogenesis of malignant ascites formation. initiating events that lead to fluid accumulation Cancer Res. 53:1993;2631-2643.
17. Garrison R.N., Kaelin L.D., Galloway R.H.et al. Malignant ascites. clinical and experimental observations Ann Surg. 203:1986;644-651.
18. Heuser L.S., Miller F.N., Gilley-Pietsch C. Protein leak from normal vasculature due to human malignant ascites. Am J Surg. 155:1988;765-769.
19. Senger D., Galli S., Dvorak A.et al. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:1983;983-985.
20. Yeo K., Wang H., Nagy J.et al. Vascular permeability factor levels in line 1 and line 10 ascites tumors and human fluids. J Cell Biol. 115:1991;421a.
21. Yeo K.T., Wang H.H., Nagy J.A.et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 53:1993;2912-2918.
22. Palacio S., Schmitt D., Viac J. Contact allergens and sodium lauryl sulphate upregulate vascular endothelial growth factor in normal keratinocytes. Br J Dermatol. 137:1997;540-544.
23. Nauck M., Roth M., Tamm M.et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol. 16:1997;398-406.